Faculty

John N. Caviness, M.D.

Clinical Studies

Electrophysiological Biomarkers for Parkinson's Disease Scottsdale/Phoenix, Ariz.
This study will determine the validity of predictive and surrogate biomarkers for the detection of Parkinson's disease and Parkinson's disease cognitive decline.

A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease Scottsdale/Phoenix, Ariz.
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease. A total of approximately 260 subjects are planned to be randomized in the study. Primary endpoint is the change from baseline in the Total Motor Score (TMS) assessment of the Unified Huntington Disease Rating Scale (UHDRS) after 26 weeks of treatment. secondary endpoints will include change from baseline in the Total Maximum Chorea (TMC) score of the UHDRS after 13 and 26 weeks of treatment and Clinical Global Impression-Improvement score after 13 and 26 weeks of treatment.
An Open Label Extension Study To Investigate the Long Term Safety, Tolerability and Efficacy of Pf-02545920 in Subjects with Huntington's Disease Who Previously Completed Study A8241021 Scottsdale/Phoenix, Ariz.
The purpose of this study is an extension following study A8241021 to assess the long-term safety, tolerability and effectiveness of PF-02545920 in patients with Huntington's disease.